Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
Alpha Tau Medical Ltd. (NASDAQ: DRTS) will participate in the Barclays 26th Annual Global Healthcare Conference to showcase its innovative alpha-radiation cancer therapy Alpha DaRT™ on March 12th and 13th, 2024, in Miami, FL.
02/26/2024 - 08:30 AM
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th , 2024.
Event: Barclays 26th Annual Global Healthcare Conference Format: 1-on-1 Meetings Date: March 12-13, 2024 Location: Miami, FL
Please reach out to your Barclays representative to schedule a one-on-one meeting.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
IR@alphatau.com
Alpha Tau Medical Ltd. will participate in the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th, 2024.
Alpha Tau Medical Ltd. has developed the innovative alpha-radiation cancer therapy Alpha DaRT™.
The Barclays 26th Annual Global Healthcare Conference will take place in Miami, FL.
Interested parties can reach out to their Barclays representative to schedule a one-on-one meeting with Alpha Tau Medical Ltd. at the conference.
DRTS Rankings
#3415 Ranked by Stock Gains
DRTS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
About DRTS
alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.
